Price cap on 2 key cancer drugs increased by 50%
The National Pharmaceutical Pricing Authority (NPPA) has increased the price caps for two essential cancer drugs, Carboplatin and Cisplatin, by 50%. The decision aims to address supply shortages caused by rising raw material costs and ensure the continued availability of these life-saving medicines.
Why it matters
Balancing drug affordability with manufacturer viability is a critical public health challenge, especially for essential chemotherapy treatments.
Price cap on 2 key cancer drugs increased by 50% | India News - The Times of India
The article reports on a government regulatory decision and the rationale provided by the authority without editorializing.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in